Kosuke Doki
Overview
Explore the profile of Kosuke Doki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watanabe Y, Doki K, Sekine I, Hara H, Homma M
Ther Drug Monit
. 2025 Feb;
PMID: 40019946
Background: Hand-foot syndrome (HFS) is a common adverse event associated with lenvatinib treatment. Lenvatinib dose adjustment using therapeutic drug monitoring may be beneficial in the management of HFS, as symptoms...
2.
Oda S, Doki K, Obara N, Suzuki Y, Chiba S, Homma M
Ther Drug Monit
. 2025 Feb;
PMID: 39908415
Background: The administration of eltrombopag, used to restore low blood count, demonstrates a positive interference of blood bilirubin levels when analyzed through the diazo assay. However, research on bilirubin measurements...
3.
Doki K, Yoshida K, Usui J, Takahashi K, Oda T, Yamagata K, et al.
Clin Transplant
. 2024 Sep;
38(10):e15471.
PMID: 39324931
Introduction: A limited sampling strategy (LSS) for estimating the area under the plasma concentration-time curve (AUC) of the immunosuppressant mycophenolic acid (MPA) is used for therapeutic drug monitoring (TDM) in...
4.
Hamano J, Higashibata T, Kessoku T, Kajiura S, Hirakawa M, Oyamada S, et al.
J Clin Oncol
. 2024 Sep;
42(35):4206-4217.
PMID: 39255425
Purpose: Opioid-induced constipation is the most frequent and non-self-limiting adverse effect of opioid analgesia, reducing adherence and interfering with pain relief. This clinical trial aimed to clarify the preventive effect...
5.
Nagafuji M, Fujiyama S, Doki K, Ishii R, Okada Y, Hanaki M, et al.
J Pediatr
. 2024 Sep;
276:114285.
PMID: 39233116
Objective: To assess the role of prostaglandin E by measuring blood prostaglandin E metabolite (PGEM) concentrations in preterm infants with patent ductus arteriosus (PDA). Study Design: A prospective observational study...
6.
Mukai Y, Sugii N, Doki K, Homma M
Biomed Chromatogr
. 2024 Jul;
38(9):e5955.
PMID: 38973552
Ceftriaxone (CTRX) is a commonly used cephalosporin antibiotic. It is suggested that monitoring plasma/serum concentrations is helpful for its safe use. This study aimed to develop and validate an analytical...
7.
Ohkubo M, Seo E, Doki K, Suzuki Y, Sekine I, Homma M
Biol Pharm Bull
. 2024 May;
47(5):941-945.
PMID: 38735754
Hepatitis B virus reactivation (HBV-R) is a serious complication that can occur in patients with resolved HBV infection during cancer chemotherapy. We examined the levels of HBV surface antibody (HBsAb)...
8.
Doki K, Hashimoto N, Yoshida K, Homma M
Clin Pharmacol Ther
. 2023 Dec;
115(5):1015-1024.
PMID: 38093601
Although various lipophilic drugs are bound to lipoproteins, lipoprotein binding in plasma is not usually considered in current physiologically-based pharmacokinetic (PBPK) models. Amiodarone is extensively bound to serum triglyceride-rich lipoproteins....
9.
Mukai Y, Doki K, Suzuki Y, Homma M
Br J Clin Pharmacol
. 2023 Oct;
90(1):368-369.
PMID: 37875351
No abstract available.
10.
Kaneko T, Doki K, Yamada T, Yamamoto Y, Moriwaki T, Suzuki Y, et al.
Cancer Chemother Pharmacol
. 2023 Jul;
92(4):271-278.
PMID: 37458784
Purpose: Considerable amounts of injected immunoglobulin G-based therapeutic monoclonal antibodies, such as ramucirumab, are distributed into ascites. This study aimed to examine the effect of massive ascites on ramucirumab pharmacokinetics...